HC Wainwright Reiterates “Buy” Rating for Abeona Therapeutics (NASDAQ:ABEO)
HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. Other research analysts also recently issued research reports about the company. StockNews.com upgraded Abeona Therapeutics […]
HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. Other research analysts also recently issued research reports about the company. StockNews.com upgraded Abeona Therapeutics […]
